Mary Remm
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,832 of the $3,842 with a category attached, or 73.7%. It is spread thinly across 40 manufacturers, the largest accounting for just 19.8%. Among family clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $34.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$759
- Pfizer$272
- Beone Medicines USA, Inc.$202
- Johnson & Johnson$185
- AbbVie$164
- Merck$141
- plus $2K from 34 others
What the payments were for
- Travel & lodging$75920%
- Food & beverage$2,83274%
- Education$2517%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 3 | $759 |
| Pfizer | 7 | $272 |
| Beone Medicines USA, Inc. | 3 | $202 |
| Johnson & Johnson | 4 | $185 |
| AbbVie | 7 | $164 |
| Merck | 8 | $141 |
| Daiichi Sankyo Inc. | 6 | $141 |
| Syndax Pharmaceuticals, Inc. | 2 | $138 |
| AstraZeneca(2 entities) | 5 | $134 |
| Incyte Corporation | 5 | $127 |
| Sanofi | 6 | $126 |
| Exelixis Inc. | 1 | $125 |
| Mirati Therapeutics, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 4 | $93 |
| Astellas Pharma US Inc | 3 | $88 |
| Genentech USA, Inc. | 4 | $83 |
| Pharmaessentia USA Corporation | 4 | $79 |
| Lilly USA, LLC | 4 | $73 |
| Histosonics, Inc. | 1 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $69 |
| Bayer | 3 | $46 |
| Genmab U.S., Inc. | 1 | $45 |
| Eisai Inc. | 2 | $44 |
| Novartis | 2 | $43 |
| Gilead | 2 | $42 |
| Sanofi-aventis U.S. LLC | 1 | $42 |
| Octapharma USA, Inc. | 1 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $37 |
| AVEO Pharmaceuticals, Inc. | 2 | $36 |
| ADC Therapeutics America, Inc. | 2 | $36 |
| Seagen Inc. | 2 | $34 |
| Beigene USA, Inc. | 1 | $29 |
| Rigel Pharmaceuticals, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Deciphera Pharmaceuticals Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,842 in reported general payments places this provider in the 90th percentile of 809 family providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BosulifBosutinib | 12 | $117,043 |
| EliquisApixaban | 31 | $25,925 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 59 | $1,079 |
| Hydroxyurea | 29 | $610 |
| Levothyroxine Sodium | 52 | $481 |
| Anastrozole | 31 | $392 |
| Tamoxifen Citrate | 17 | $373 |
| Potassium Chloride | 47 | $351 |
| Letrozole | 16 | $323 |
| Warfarin Sodium | 26 | $148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerBosulif, Eliquis | $272 | $142,96843 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Nebraska.
Other family in Omaha
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Brittany MatneyOmaha$14K
- Sara LegleiterOmaha$12K
- Jasper KaufmanOmaha$10K
- Stacy NiemiOmaha$10K
- Amy RuddickOmaha$10K
- Michaela AbbottOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.